The drugs that shift workers are taking to help them stay awake or get to sleep are not of much benefit and they may do more harm than good, says a review of available research.
"For lots of people who do shift work, it would be really useful if they could take a pill that would help them go to sleep or stay awake at the right time," said lead author of the review, Juha Liira, who is based at the Finnish Institute of Occupational Health in Helsinki, Finland.
"But from what we have seen in our review, there is not good evidence that these drugs can be considered for more than temporary use and some may have quite serious side effects," Liira added.
The review included 15 trials involving a total of 718 people. In nine trials, the over-the-counter hormone drug melatonin helped shift workers sleep for around 24 minutes longer during the night or day, compared to placebos.
However, it did not help them get to sleep any quicker.
Data from only one trial of the hypnotic drug zoplicone was available. The drug was no more effective than placebos for helping shift workers sleep during the day.
Modafinil and armodafinil, used by shift workers in one and two trials respectively, increased alertness and reduced sleepiness.
However, they also caused headaches, nausea and a rise in blood pressure in a substantial number of people.
The study appeared in Cochrane Reviews.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
